CD274 and small cell lung carcinoma: The significance of ASTRUM-005 lies in it being the first global Phase 3 study to validate a PD-1 inhibitor in this setting—previous successful trials had used PD-L1 inhibitors—leading to regulatory approvals and establishing a new standard of care for ES-SCLC [57].